The Indianapolis-based drugmaker filed a suit in federal court this month, challenging the U.S. Food and Drug Administration’s ruling that the company’s experimental obesity treatment not a biological product.
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell the compounded versions has intensified.
The Joint Center of Excellence for Point of Care Precision Medicine aims to develop better personalized care for patients with diabetes, cancer, Alzheimer’s disease and pediatric rare disease.
A complaint filed last week with the Indiana Department of Insurance alleges gross violations of care at an Indianapolis behavioral health facility.
The pharmacy chain was accused of submitting false payment claims to Medicare, Medicaid and other federal health care programs between 2009 and 2020 for prescriptions that were processed but never picked up.
Nationally, the average cost of employer-sponsored health plans is expected to grow 9% next year if companies don’t find ways to cut costs, according to an Aug. 15 report by professional services firm Aon.
The providers—including the regional Planned Parenthood affiliate—had sought a permanent injunction to expand the near-total ban’s medical exemptions and to block its requirement that abortions can only be performed at hospitals.
IU Health Plans offers Medicare Advantage plans in 36 counties serving 19,000 members as well as fully insured commercial plans for 12,000 more people.
Superior Court Judge Timothy Oakes ruled in favor of the Indiana Department of Health, which stopped sharing the reports following the state’s adoption of a near-total abortion ban.
FDA officials noted that the drop in vaping didn’t coincide with a rise in other tobacco industry products, such as nicotine pouches, which have surged in use among adults.
Last year’s inspection numbers were down almost 40% from the pre-pandemic period, when the FDA averaged about 4,300 annual inspections.
The plant has been linked to the deaths of at least nine people and hospitalizations of about 50 others in 18 states, including Indiana.
Lilly said its new option will help millions of adults with obesity access the medicine they need, including those not eligible for the Zepbound savings card program, those without employer coverage, and those who need to self-pay outside of insurance.
The five-year-old, clinical-stage drugmaker has already raised more than $213 million to develop therapeutics to treat rare endocrine disorders, a huge amount for a startup.
With the Food and Drug Administration’s clearance, Pfizer and Moderna are set to begin shipping millions of doses.
Legislators on the state’s Medicaid Advisory Committee spent hours Wednesday questioning state officials about Indiana’s ongoing lawsuit over provisions of the Healthy Indiana Plan.
The longest continuous study of Indianapolis-based Lilly’s drug Zepbound to date included more than 1,000 patients.
Lilly is moving about 200 scientists and researchers who had worked in nearby Cambridge, Massachusetts, to the new center, and plans to add about 300 employees.
The lab, which will be located on the second floor of the 11-story IU Medical Education and Research Building, will emphasize hands-on physical dissection as a vital component of medical training.
The Eli Lilly and Co. and Purdue University Research Alliance Center involves more than 50 researchers and 65 graduate students.
